-

03:56:07 PM

ALT Stock News

ALT - Altimmune Inc

06/17/22 7:30 AM

Nasdaq : ALT

clinical trial

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research,

RHEA-AI

neutral

06/03/22 7:30 AM

Nasdaq : ALT

conferences

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global Healthcare

RHEA-AI

neutral

05/31/22 7:30 AM

Nasdaq : ALT

conferencesclinical trial

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver

RHEA-AI

neutral

05/20/22 7:30 AM

Nasdaq : ALT

conferencesclinical trial

Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5 th Global NASH Congress on May 26-27, 2022, in London,

RHEA-AI

neutral

05/16/22 7:30 AM

Nasdaq : ALT

conferences

Altimmune to Present at Upcoming Investor Conferences

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment

RHEA-AI

neutral

05/12/22 7:00 AM

Nasdaq : ALT

earnings

Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate

RHEA-AI

neutral

05/05/22 7:30 AM

Nasdaq : ALT

conferencesearnings

Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update. Altimmune management will host

RHEA-AI

neutral

04/01/22 7:00 AM

Nasdaq : ALT

clinical trial

Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced

RHEA-AI

neutral

03/15/22 7:01 AM

Nasdaq : ALT

earnings

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced

RHEA-AI

neutral

03/08/22 7:00 AM

Nasdaq : ALT

conferencesearnings

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022. Altimmune management will host a conference call

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ALT Data

Websitewww.altimmune.com
CeoVipin Garg
Security nameAltimmune Inc
Issue typecs
Sic code2834
Employees43
Tags
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address910 Clopper Rd Ste 201S
StateMaryland
CityGaithersburg
Zip20878-1361
CountryUS
Phone12406541450

About Altimmune Inc

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).